مورد إلكتروني

Friedreich's Ataxia: from the (GAA)n repeat mediated silencing to new promising molecules for therapy.

التفاصيل البيبلوغرافية
العنوان: Friedreich's Ataxia: from the (GAA)n repeat mediated silencing to new promising molecules for therapy.
المصدر: Cerebellum, 8 (3
بيانات النشر: 2009-09
تفاصيل مُضافة: Marmolino, Daniele
Acquaviva, Fabio
نوع الوثيقة: Electronic Resource
مستخلص: Friedreich's ataxia (FRDA) is a neurodegenerative disease due to a pathological expansion of a GAA triplet repeat in the first intron of the FXN gene encoding for the mitochondrial protein frataxin. The expansion is responsible for most cases of FRDA through the formation of a nonusual B-DNA structure and heterochromatin conformation that determine a direct transcriptional silencing and the subsequent reduction in frataxin expression. Among other functions, frataxin is an iron chaperone central for the assembly of iron-sulfur clusters in mitochondria; its reduction is associated with iron accumulation in mitochondria, increased cellular sensitivity to oxidative stress and cell damage. There is, nowadays, no effective therapy for FRDA and current therapeutic strategies mainly act to slow down the consequences of frataxin deficiency. Therefore, drugs that are able to increase the amount of frataxin are excellent candidates for a rational approach to FRDA therapy. Recently, several drugs have been assessed for their ability to increase the amount of cellular frataxin, including human recombinant erythropoietin, histone deacetylase inhibitors, and the PPAR-gamma agonists.
Journal Article
Research Support, Non-U.S. Gov't
Review
SCOPUS: re.j
info:eu-repo/semantics/published
مصطلحات الفهرس: Neurologie, Sciences bio-médicales et agricoles, Animals, Antioxidants -- pharmacology -- therapeutic use, Chlorofluorocarbons, Methane -- pharmacology -- therapeutic use, Enzyme Inhibitors -- pharmacology -- therapeutic use, Friedreich Ataxia -- drug therapy -- genetics -- therapy, Gene Silencing -- physiology, Heterochromatin -- metabolism, Histone Deacetylases -- metabolism, Histones -- metabolism, Humans, Iron -- metabolism, Iron Chelating Agents -- pharmacology -- therapeutic use, Iron-Binding Proteins -- genetics, Models, Biological, PPAR gamma -- metabolism, Signal Transduction -- drug effects, Transcription Factors -- metabolism, Trinucleotide Repeats -- genetics, Frataxin, Friedreich's ataxia, FXN gene, GAA triplet repeat, Neurodegeneration, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL: http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/148500Test
http://worldcat.org/search?q=on:EQY+http://difusion-oai.ulb.ac.be/oai/request+DCG_ENTIRE_REPOSITORY+CNTCOLLTest
الإتاحة: Open access content. Open access content
ملاحظة: No full-text files
English
أرقام أخرى: EQY oai:dipot.ulb.ac.be:2013/148500
uri/info:doi/10.1007/s12311-008-0084-2
uri/info:pmid/19165552
uri/info:scp/68449096810
1363805155
المصدر المساهم: UNIVERSITE LIBRE DE BRUXELLES
From OAIster®, provided by the OCLC Cooperative.
رقم الانضمام: edsoai.on1363805155
قاعدة البيانات: OAIster